SILVER SPRING, Maryland — Clinical trials necessarily involve the unknown, one of which might be how the choice of a statistical model will affect the outcome. This was the case for the application for the NeuroPace RNS device for medical-refractory epilepsy, which came through a Feb. 22 advisory committee hearing in good form despite a difference of opinion about the applicability of statistical models.